Published : Aug-2021
No. of Pages : 61
| About GlobalData
1 HER2-Positive Breast Cancer: Executive Summary
1.1 Catalyst
1.2 Related Reports
1.3 Upcoming Reports
2 Epidemiology
2.1 Disease Background
2.2 Risk Factors and Comorbidities
2.3 Global and Historical Trends
2.4 Forecast Methodology
2.4.1 Sources Used
2.4.2 Forecast Assumptions and Methods
2.5 Epidemiological Forecast for All Invasive and HER2-Positive Breast Cancer (2020-2030)
2.5.1 Diagnosed Incident Cases of All Invasive Breast Cancer
2.5.2 Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer
2.5.3 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer
2.5.4 Diagnosed Incident Cases of HER2+/HR- Breast Cancer
2.5.5 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stages
2.5.6 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stages
2.5.7 Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status
2.5.8 Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status
2.5.9 Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression
2.5.10 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression
2.5.11 Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression
2.5.12 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis
2.5.13 Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis
2.5.14 Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression
2.5.15 Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer
2.6 Discussion
2.6.1 Epidemiological Forecast Insight
2.6.2 COVID-19 Impact
2.6.3 Limitations of Analysis
2.6.4 Strengths of Analysis
3 Appendix
3.1 Bibliography
3.2 About the Authors
3.2.1 Epidemiologist
3.2.2 Reviewers
3.2.3 Global Director of Therapy Analysis and Epidemiology
3.2.4 Global Head and EVP of Healthcare Operations and Strategy
3.3 Contact Us
List of Tables
Table 1: Summary of Newly Added Data Types
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for All Invasive HER2-Positive Breast Cancer
List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of HER2+/HR+ Breast Cancer, Women, N, Ages ?18 Years, 2020 and 2030
Figure 2: 8MM, Diagnosed Incident Cases of HER2+/HR- Breast Cancer, Women, N, Ages ?18 Years, 2020 and 2030
Figure 3 : 8MM, Diagnosed Incidence of HER2+/HR+ Breast Cancer, Ages ?18 Years, Women, Cases per 100,000 Population, 2010?2030
Figure 4: 8MM, Diagnosed Incidence of HER2+/HR- Breast Cancer, Ages ?18 Years, Women, Cases per 100,000 Population, 2010?2030
Figure 5: 8MM, Sources Used and Not Used for Diagnosed Incident Cases of All Invasive Breast Cancer
Figure 6: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer
Figure 7: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Stage
Figure 8: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Menopausal Status
Figure 9: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by PD-1 and PD-L1 Expression
Figure 10: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Ki67, NTRK, and RET Expression
Figure 11: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by Bone and Brain Metastasis
Figure 12: 8MM, Sources Used for Diagnosed Incident Cases of HER2+/HR+ and HER2+/HR- Breast Cancer by IHC3+ Expression
Figure 13: 8MM, Sources Used for Five-Year Diagnosed Prevalent Cases of HER2+/HR+ and HER2+/HR- Breast Cancer
Figure 14: 8MM, Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages ?18 Years, N, 2020
Figure 15: 8MM, Age-Specific Diagnosed Incident Cases of All Invasive Breast Cancer, Women, Ages ?18 Years, N, 2020
Figure 16: 8MM, Diagnosed Incident Cases of HER2+/HR+ Breast Cancer, Women, Ages ?18 Years, N, 2020
Figure 17: 8MM, Diagnosed Incident Cases of HER2+/HR- Breast Cancer, Women, Ages ?18 Years, N, 2020
Figure 18: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Stage, Women, Ages ?18 Years, N, 2020
Figure 19: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Stage, Women, Ages ?18 Years, N, 2020
Figure 20: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR+ Breast Cancer by Menopausal Status, Women, Ages ?18 Years, %, 2020
Figure 21: 8MM, Proportion of Diagnosed Incident Cases of HER2+/HR- Breast Cancer by Menopausal Status, Women, Ages ?18 Years, %, 2020
Figure 22: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer by PD-1 and PD-L1 Expression, Women, Ages ?18 Years, N, 2020
Figure 23: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Ki67 Expression, Women, Ages ?18 Years, N, 2020
Figure 24: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with NTRK and RET Expression, Women, Ages ?18 Years, N, 2020
Figure 25: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Bone Metastasis, Women, Ages ?18 Years, N, 2020
Figure 26: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with Brain/CNS Metastasis, Women, Ages ?18 Years, N, 2020
Figure 27: 8MM, Diagnosed Incident Cases of HER2-Positive Breast Cancer with IHC3+ Expression, Women, Ages ?18 Years, N, 2020
Figure 28: 8MM, Five-Year Diagnosed Prevalent Cases of HER2-Positive Breast Cancer, Women, Ages ?18 Years, N, 2020
